menu

Pulmonary Arterial Hypertension: Screening, Diagnosis, and Optimizing Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Pulmonary Arterial Hypertension: Screening, Diagnosis, and Optimizing Management

1.00 credits
60 Minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Learn how to use guideline recommendations to establish a diagnosis of pulmonary arterial hypertension (PAH), develop evidence-based individualized treatment plans, and explore innovative therapies under investigation for PAH management. Hear from expert faculty on how to integrate the patient’s perspective when personalizing management plans for PAH.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author
    Vallerie V. McLaughlin, MD
    Endowed Professor of Cardiovascular Medicine
    Interim Chief Clinic Officer
    Ambulatory Care Services
    Director
    Pulmonary Hypertension Program
    University of Michigan
    Ann Arbor, Michigan

    Vallerie McLaughlin, MD: consultant/advisor/speaker: Aerami, Aerovate, Caremark, Corvista, Enzyvant, Gossamer-Bio, Janssen, Merck, United Therapeutics, Vertex; researcher: Aerovate, Enzyvant, Gossamer-Bio, Janssen, Merck, Sonovie. 

    The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Melisa Wilson, DNP, APRN, ACNP, BC as noted below:

    Melisa A. Wilson, DNP, APRN, ACNP, BC: consultant/advisor/speaker: Bayer, Gossamer Bio, Janssen, Merck, United Therapeutics.

  • Target Audience

    The program is intended for heart failure specialists, cardiologists (physicians and fellows), internists, nurses, physician associates, and other advanced practice providers who care for patients with PAH.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Employ guideline recommendations to establish a diagnosis of pulmonary arterial hypertension
    • Develop evidence-based personalized treatment plans for patients with PAH
    • Describe therapy approaches under investigation for management of PAH
    • Integrate strategies to include the patient’s perspective when personalizing management plans for PAH
  • Accreditation and Credit Designation Statements

     

    In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education

    CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

    Physician Associate Continuing Medical Education

      

    Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until November 19, 2024. PAs should only claim credit commensurate with the extent of their participation.

    American Board of Internal Medicine Maintenance of Certification

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

    By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).



  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)


    Provided by Clinical Care Options, LLC. 

  • Commercial Support

    This activity is supported through an independent educational grant from Merck & Co.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Goal Statement

    The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Pulmonary Arterial Hypertension (PAH).

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Learn how to use guideline recommendations to establish a diagnosis of pulmonary arterial hypertension (PAH), develop evidence-based individualized treatment plans, and explore innovative therapies under investigation for PAH management. Hear from expert faculty on how to integrate the patient’s perspective when personalizing management plans for PAH.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author
    Vallerie V. McLaughlin, MD
    Endowed Professor of Cardiovascular Medicine
    Interim Chief Clinic Officer
    Ambulatory Care Services
    Director
    Pulmonary Hypertension Program
    University of Michigan
    Ann Arbor, Michigan

    Vallerie McLaughlin, MD: consultant/advisor/speaker: Aerami, Aerovate, Caremark, Corvista, Enzyvant, Gossamer-Bio, Janssen, Merck, United Therapeutics, Vertex; researcher: Aerovate, Enzyvant, Gossamer-Bio, Janssen, Merck, Sonovie. 

    The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Melisa Wilson, DNP, APRN, ACNP, BC as noted below:

    Melisa A. Wilson, DNP, APRN, ACNP, BC: consultant/advisor/speaker: Bayer, Gossamer Bio, Janssen, Merck, United Therapeutics.

  • Target Audience

    The program is intended for heart failure specialists, cardiologists (physicians and fellows), internists, nurses, physician associates, and other advanced practice providers who care for patients with PAH.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Employ guideline recommendations to establish a diagnosis of pulmonary arterial hypertension
    • Develop evidence-based personalized treatment plans for patients with PAH
    • Describe therapy approaches under investigation for management of PAH
    • Integrate strategies to include the patient’s perspective when personalizing management plans for PAH
  • Accreditation and Credit Designation Statements

     

    In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education

    CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

    Physician Associate Continuing Medical Education

      

    Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until November 19, 2024. PAs should only claim credit commensurate with the extent of their participation.

    American Board of Internal Medicine Maintenance of Certification

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

    By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).



  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)


    Provided by Clinical Care Options, LLC. 

  • Commercial Support

    This activity is supported through an independent educational grant from Merck & Co.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Goal Statement

    The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Pulmonary Arterial Hypertension (PAH).

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 May 2024